ReviewAmerican journal of hematology2022

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.

Elena Inzoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.